← Zura Bio Ltd (ZURA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Zura Bio Ltd (ZURA)
Biological Products, (No Diagnostic Substances) · market cap $410M · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
2
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Zura Bio Ltd (ZURA) is a clinical-stage biotech with a market cap of ~$483M developing tibulizumab, a biologic in Phase 2 trials for Hidradenitis Suppurativa (HS) and Systemic Sclerosis (SSc). The company holds $225.6M in cash (~35.8 months runway) and faces two key Phase 2 readouts estimated in late 2026, with a third in mid-2027.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
- 2026-11-15 (est.)Phase 2 · Tibulizumab Dose Aimp 7/10
- 2027-05-15 (est.)Phase 2 · Tibulizumabimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Tibulizumab Dose A | Phase 2 | Hidradenitis Suppurativa (HS) |
| Tibulizumab | Phase 2 | Systemic Sclerosis (SSc) |
Price & technical context
3-month
-22.0%
6-month
-30.7%
12-month
+3.5%
52-wk range
$3.21–$7.04
vs 50-day MA
-21.3%
vs 200-day MA
-21.5%
Realized vol
78.7%
Max drawdown
-79.7%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ZURA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.